Inflammatory Cytokines and Survival Factors from Serum Modulate Tweak-Induced Apoptosis in PC-3 Prostate Cancer Cells

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Sanz, Ana Belen ^a   Sanchez Niño, Maria Dolores ^a   Carrasco, Susana ^b   Manzarbeitia, Felix ^c   Ruiz Andres, Olga ^b   Selgas, Rafael ^a   Ruiz Ortega, Marta ^b   Gonzalez Enguita, Carmen ^c   Egido, Jesus ^b   Ortiz, Alberto ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b Section of Nephrology   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYTOCHROME C; CYTOKINE RECEPTOR; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; GAMMA INTERFERON; PROTEIN BAX; PROTEIN BCL XL; RECOMBINANT CYTOKINE; RECOMBINANT TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INTERFERON-GAMMA; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTORS;

EID: 84867559091     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047440     Document Type: Article

References (63)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300. caac.20073 10.3322/caac.20073 [doi].
2. Hwang C, Heath EI (2010) Angiogenesis inhibitors in the treatment of prostate cancer. J Hematol Oncol 3: 26. 1756-8722-3-26; 10.1186/1756-8722-3-26 [doi].
3. Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ, (1983) Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A 80: 5397-5401.
4. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, et al. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72: 3666-3670.
5. Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, et al. (1985) Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 260: 2345-2354.
6. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, et al. (1984) Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312: 724-729.
7. Royuela M, Rodriguez-Berriguete G, Fraile B, Paniagua R, (2008) TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate. Histol Histopathol 23: 1279-1290.
8. Nastiuk KL, Krolewski JJ (2008) FLIP-ping out: death receptor signaling in the prostate. Cancer Biol Ther 7: 1171-1179. 6712.
9. Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB (2004) Death receptor-induced cell death in prostate cancer. J Cell Biochem 91: 70-99. doi:10.1002/jcb.10707.
10. Tenniswood M, Lee EC (2004) On the trail of cell death pathways in prostate cancer. Cancer Biol Ther 3: 769-771. 1028.
11. Bucur O, Ray S, Bucur MC, Almasan A (2006) APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci 11: 1549-1568. 1903.
12. Perez-Martinez FC, Alonso V, Sarasa JL, Nam-Cha SG, Vela-Navarrete R, et al. (2007) Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand. J Clin Pathol 60: 290-294. jcp.2006.037853; 10.1136/jcp.2006.037853 [doi].
13. O'Kane HF, Watson CJ, Johnston SR, Petak I, Watson RW, et al. (2006) Targeting death receptors in bladder, prostate and renal cancer. J Urol 175: 432-438. S0022-5347(05)00160-6; 10.1016/S0022-5347(05)00160-6 [doi].
14. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, et al. (1997) TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272: 32401-32410.
15. Sanz AB, Sanchez-Nino MD, Ortiz A (2011) TWEAK, a multifunctional cytokine in kidney injury. Kidney Int 80: 708-718. ki2011180; 10.1038/ki.2011.180 [doi].
16. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, et al. (2005) TWEAK induces liver progenitor cell proliferation. J Clin Invest 115: 2330-2340.
17. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, et al. (1999) TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 274: 8455-8459.
18. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, et al. (2005) TWEAK attenuates the transition from innate to adaptive immunity. Cell 123: 931-944.
19. Nakayama M, Harada N, Okumura K, Yagita H, (2003) Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun 306: 819-825.
20. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, et al. (2005) The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 280: 3483-3492.
21. Mittal A, Bhatnagar S, Kumar A, Lach-Trifilieff E, Wauters S, et al. (2010) The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol 188: 833-849. jcb.200909117; 10.1083/jcb.200909117 [doi].
22. Wang D, Fung JN, Tuo Y, Hu L, Chen C (2010) TWEAK/Fn14 promotes apoptosis of human endometrial cancer cells via caspase pathway. Cancer Lett 294: 91-100. S0304-3835(10)00053-4; 10.1016/j.canlet.2010.01.027 [doi].
23. Novoyatleva T, Diehl F, van Amerongen MJ, Patra C, Ferrazzi F, et al. (2010) TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res 85: 681-690. cvp360; 10.1093/cvr/cvp360 [doi].
24. Tiller G, Fischer-Posovszky P, Laumen H, Finck A, Skurk T, et al. (2009) Effects of TWEAK (TNF superfamily member 12) on differentiation, metabolism, and secretory function of human primary preadipocytes and adipocytes. Endocrinology 150: 5373-5383. en.2009-0488; 10.1210/en.2009-0488 [doi].
25. Dionne S, Levy E, Levesque D, Seidman EG (2010) PPARgamma ligand 15-deoxy-delta 12,14-prostaglandin J2 sensitizes human colon carcinoma cells to TWEAK-induced apoptosis. Anticancer Res 30: 157-166. 30/1/157.
26. Culp PA, Choi D, Zhang Y, Yin J, Seto P, et al. (2010) Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res 16: 497-508. 1078-0432.CCR-09-1929; 10.1158/1078-0432.CCR-09-1929 [doi].
27. Michaelson JS, Burkly LC (2009) Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Results Probl Cell Differ 49: 145-160. doi:10.1007/400_2008_18.
28. Watts GS, Tran NL, Berens ME, Bhattacharyya AK, Nelson MA, et al. (2007) Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer 121: 2132-2139. doi:10.1002/ijc.22898.
29. Winkles JA (2008) The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 7: 411-425. nrd2488; 10.1038/nrd2488 [doi].
30. Available: http://clinicaltrials.gov/ct2/show/NCT00738764.Accessed 2012 August 6.
31. Dai L, Gu L, Ding C, Qiu L, Di W (2009) TWEAK promotes ovarian cancer cell metastasis via NF-kappaB pathway activation and VEGF expression. Cancer Lett 283: 159-167. S0304-3835(09)00228-6; 10.1016/j.canlet.2009.03.036 [doi].
32. Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, et al. (2008) The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 6: 725-734. 6/5/725; 10.1158/1541-7786.MCR-08-0005 [doi].
33. Justo P, Sanz AB, Sanchez-Nino MD, Winkles JA, Lorz C, et al. (2006) Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int 70: 1750-1758.
34. Sanz AB, Sanchez-Nino MD, Izquierdo MC, Jakubowski A, Justo P, et al. (2009) Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. J Cell Mol Med 13: 3329-3342. JCMM766; 10.1111/j.1582-4934.2009.00766.x [doi].
35. Huang M, Narita S, Tsuchiya N, Ma Z, Numakura K, et al. (2011) Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome. Carcinogenesis 32: 1589-1596. bgr182; 10.1093/carcin/bgr182 [doi].
36. Alonso V, Perez-Martinez FC, Calahorra FJ, Esbrit P (2009) Phytoestrogen modulation of bone-related cytokines and its impact on cell viability in human prostate cancer cells. Life Sci 85: 421-430. S0024-3205(09)00303-8; 10.1016/j.lfs.2009.07.005 [doi].
37. Rodriguez-Berriguete G, Fraile B, Paniagua R, Aller P, Royuela M (2012) Expression of NF-kappaB-related proteins and their modulation during TNF-alpha-provoked apoptosis in prostate cancer cells. Prostate 72: 40-50. doi:10.1002/pros.21404.
38. Sanchez-Nino MD, Sanz AB, Lorz C, Gnirke A, Rastaldi MP, Nair V, et al. (2010) BASP1 promotes apoptosis in diabetic nephropathy. J Am Soc Nephrol 21: 610-621. ASN.2009020227; 10.1681/ASN.2009020227 [doi].
39. Molano A, Lakhani P, Aran A, Burkly LC, Michaelson JS, et al. (2009) TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunol Lett 125: 119-128. S0165-2478(09)00164-3; 10.1016/j.imlet.2009.06.010 [doi].
40. Sanz AB, Justo P, Sanchez-Nino MD, Blanco-Colio LM, Winkles JA, et al. (2008) The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 19: 695-703. ASN.2007050577; 10.1681/ASN.2007050577 [doi].
41. Ortiz A, Lorz C, Catalan MP, Danoff TM, Yamasaki Y, et al. (2000) Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. Kidney Int 57: 969-981.
42. Lorz C, Ortiz A, Justo P, Gonzalez-Cuadrado S, Duque N, et al. (2000) Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. J Am Soc Nephrol 11: 1266-1277.
43. Munoz-Garcia B, Martin-Ventura JL, Martinez E, Sanchez S, Hernandez G, et al. (2006) Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 37: 2044-2053.
44. Xia LP, Fang F, Lu J, Xiao WG, (2010) [The expression of TWEAKR/Fn14 in Rheumatoid arthritis fibroblast-like synoviocytes]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 26: 575-577.
45. Moreno JA, Munoz-Garcia B, Martin-Ventura JL, Madrigal-Matute J, Orbe J, et al. (2009) The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 207: 103-110. S0021-9150(09)00334-7; 10.1016/j.atherosclerosis.2009.04.033 [doi].
46. Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, et al. (2007) A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 178: 8183-8194.
47. Schneider P, Schwenzer R, Haas E, Muhlenbeck F, Schubert G, et al. (1999) AID-IMMU1785>3.0.CO;2-U; 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U [doi].
48. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, et al. (2001) Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276: 10767-10774. 10.1074/jbc.M005196200 [doi];M005196200.
49. Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di RC, et al. (2008) Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. Int J Oncol 33: 381-388.
50. Cornforth AN, Davis JS, Khanifar E, Nastiuk KL, Krolewski JJ (2008) FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells. Oncogene 27: 4422-4433. onc200880; 10.1038/onc.2008.80 [doi].
51. Shirley S, Micheau O (2010) Targeting c-FLIP in cancer. Cancer Lett. S0304-3835(10)00485-4; 10.1016/j.canlet.2010.10.009 [doi].
52. Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, et al. (2008) TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 182: 171-184. jcb.200801010; 10.1083/jcb.200801010 [doi].
53. Kaplan MJ, Ray D, Mo RR, Yung RL, Richardson BC (2000) TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol 164: 2897-2904. ji_v164n6p2897.
54. Kaplan MJ, Lewis EE, Shelden EA, Somers E, Pavlic R, et al. (2002) The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 169: 6020-6029.
55. Kaduka Y, Takeda K, Nakayama M, Kinoshita K, Yagita H, et al. (2005) TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage. Biochem Biophys Res Commun 331: 384-390. S0006-291X(05)00669-8; 10.1016/j.bbrc.2005.03.176 [doi].
56. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Orbe J, Paramo JA,et al. (2007) Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 27: 916-922. 01.ATV.0000258972.10109.ff; 10.1161/01.ATV.0000258972.10109.ff [doi].
57. Martin-Ventura JL, Lindholt JS, Moreno JA, Vega de CM, Meilhac O, et al. (2010) Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis. S0021-9150(10)00908-1; 10.1016/j.atherosclerosis.2010.11.009 [doi].
58. Carrero JJ, Ortiz A, Qureshi AR, Martin-Ventura JL, Barany P, et al. (2009) Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 4: 110-118. CJN.02790608; 10.2215/CJN.02790608 [doi].
59. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lossner U, et al. (2008) Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 199: 440-444. S0021-9150(07)00679-X; 10.1016/j.atherosclerosis.2007.10.022 [doi].
60. Kim HS, Presti JC, Jr., Aronson WJ, Terris MK, Kane CJ, et al.(2010) Glycemic control and prostate cancer progression: results from the SEARCH database. Prostate 70: 1540-1546. doi:10.1002/pros.21189.
61. Snyder CF, Stein KB, Barone BB, Peairs KS, Yeh HC, et al. (2010) Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis 13: 58-64. pcan200939; 10.1038/pcan.2009.39 [doi].
62. Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, et al. (2011) Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs 3: 362-375. 16090.
63. Michaelson JS, Kelly R, Yang L, Zhang X, Wortham K, et al. (2012) The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models. Cancer Biol Ther 13. 20564.